Dentsply Sirona (XRAY) Stock Weekend Update: Dividend, Turnaround Plan, Analyst Targets

New York time check: It’s 5:02 a.m. ET on Saturday, December 27, 2025 in New York, which means U.S. stock exchanges (including Nasdaq, where Dentsply Sirona trades as XRAY) are closed right now.

With the market shut for the weekend, investors are left to digest the latest company updates and Wall Street commentary before the next regular session. The last available quote has XRAY around $11.5 per share, leaving the stock near the lower half of its $9.85–$20.60 52-week range and implying a market value in the low-$2B neighborhood. ^[1]

Where XRAY sits as the market heads into the final trading days of 2025

Dentsply Sirona is a dental products and technology company, and XRAY has become a stock that trades less like a “steady healthcare name” and more like a “turnaround in progress,” with results, guidance, and leadership moves doing most of the heavy lifting on sentiment.

Zooming out briefly: broad U.S. index ETFs were little changed into the holiday-shortened period, a reminder that individual-stock news (not macro fireworks) can dominate single-name moves this time of year.

The core fundamental story: Q3 2025 results + a reset outlook + a 24‑month “Return-to-Growth” plan

The most important fundamental anchor for XRAY right now remains the company’s third-quarter 2025 report and its accompanying strategic reset.

In that Q3 release, Dentsply Sirona reported:

Net sales of $904 million, down 5.0% reported and down 8.0% on a constant-currency basis
GAAP net loss per share of ($2.14) (including a large non-cash impairment)
Adjusted EPS of $0.37
Segment and geography detail that showed meaningful U.S. weakness (U.S. net sales down 22.2% year over year in the quarter on the company’s reported basis for the U.S. line item) ^[2]

Management didn’t sugarcoat it. CEO Daniel (Dan) Scavilla said, “Third quarter results fell short of our expectations…” while rolling out a “Return-to-Growth” action plan intended to improve performance over the next 24 months. ^[3]

The revised full-year 2025 outlook (the numbers investors keep re-checking)

In the same Q3 release, Dentsply Sirona revised its 2025 outlook to:

Net sales:$3.6B to $3.7B
Constant-currency sales:(5%) to (4%) year-over-year
Adjusted EPS: approximately $1.60
The company also flagged that this outlook “reflects the current state of tariffs and trade policy,” keeping trade uncertainty on the risk dashboard for anyone modeling margins into 2026. ^[4]

Why the GAAP loss looked so ugly (and why investors separate “cash” from “accounting” here)

One reason XRAY has been hard to value on simple headline metrics is the presence of large non-cash impairment charges. In Q3 2025, the company recorded a $263 million impairment (net of tax) tied to goodwill and indefinite-lived intangibles, which management linked to lower-than-expected volumes in parts of the business (particularly in the U.S.) and tariff impacts. ^[5]

That doesn’t make the issue disappear—impairments often signal that prior growth expectations didn’t pan out—but it does change how investors think about near-term cash generation versus accounting losses.

Leadership churn and “adult supervision” for the turnaround

Turnarounds are part operations, part incentives, and part organizational plumbing. Dentsply Sirona’s recent leadership updates have been a major theme:

In the Q3 results release, the company disclosed that CFO Matt Garth had departed and that a search for a successor was underway. ^[6]
On November 25, 2025, an SEC filing stated that Michael Pomeroy was appointed interim CFO, while CEO Dan Scavilla would continue as the company’s principal financial officer for SEC filing purposes until a permanent CFO is named. ^[7]
The Q3 release also highlighted leadership additions aimed at execution, including a Chief Transformation Officer role to drive the Return-to-Growth plan. ^[8]

For investors, the optimistic interpretation is “fresh operators and tighter accountability.” The cautious interpretation is “reorganizations take time, and the clock is running on credibility.”

The dividend: a real cash return, a high yield, and a calendar item investors should not miss

On December 15, 2025, Dentsply Sirona announced a quarterly cash dividend of $0.16 per share (annual rate $0.64), payable January 9, 2026, to shareholders of record as of December 26, 2025. ^[9]

At a share price around $11.5, that annual dividend implies a forward yield of roughly 5.6% (math: $0.64 / $11.52). ^[10]

What matters before the next session: many quote services list Dec. 26, 2025 as the relevant ex-dividend date. That means anyone buying after that cutoff generally should not expect to receive the January 9 dividend—though the mechanics can be broker- and settlement-dependent, especially around weekends and holidays. ^[11]

Regulatory and legal “overhang” update: SEC investigation closed without enforcement (as of Oct. 2025)

One headline that continues to echo in XRAY valuation discussions is the conclusion of a long-running SEC matter.

A Dentsply Sirona Form 8‑K dated October 14, 2025 states that the SEC Division of Enforcement concluded its investigation (which began in May 2022) and did not intend to recommend enforcement action against the company. ^[12]

That doesn’t automatically erase all historical concerns investors may have had around controls and reporting, but it does remove a major source of uncertainty that can depress multiples.

Insider activity: a signal worth noting, but not a crystal ball

Insider transactions don’t predict the future, but they can influence sentiment—especially in smaller or turnaround narratives.

A Reuters/Refinitiv item reported that director Gregory T. Lucier filed a Form 144 proposing the sale of 82,200 shares, with an approximate sale date listed as December 8, 2025. ^[13]

As always: Form 144 filings can reflect diversification, tax planning, or prearranged selling—not necessarily a bearish view. But in a stock with elevated skepticism, the market tends to notice.

Balance sheet and financing moves: credit agreement amendments and a long-dated notes issuance

For investors who track financial flexibility closely, Dentsply Sirona has also made notable capital structure moves during 2025:

A June 2025 SEC filing references a First Amendment to the Credit Agreement dated June 3, 2025, along with amendments involving its note purchase agreement. ^[14]
Another June 2025 SEC filing states the company issued $550 million of 8.375% Fixed-to-Fixed Reset Rate Junior Subordinated Notes due 2055 on June 12, 2025. ^[15]

These actions can be read two ways:

Pro: extending maturities and maintaining liquidity while executing a turnaround
Con: a reminder that cost of capital matters, and leverage/covenants can constrain optionality if operations don’t improve

Analyst forecasts and price targets: cautious consensus, but upside implied by some models

Street views on XRAY are not monolithic. Depending on the data provider and analyst set, the “consensus” ranges from neutral to mildly constructive—often paired with the caveat that execution risk is high.

A Nasdaq-hosted piece citing Fintel data reported that Barrington Research maintained an Outperform rating in mid-December and cited an average one-year price target around $12.99 (with a range roughly $11.11 to $17.85), implying mid-teens percent upside from the cited reference price. ^[16]

Other public aggregators show a wider spread. For example, one compilation lists a “Hold” consensus with an average target in the mid-teens and a high target extending into the low $20s. ^[17]

How to interpret this (without getting hypnotized by a single number):

When price targets cluster only modestly above the current price, it often signals “wait-and-see” confidence—analysts see a path to stabilization, but not enough evidence yet for aggressive rerating.
The wide gap between low and high targets usually means the market is arguing about execution: the bull case assumes the Return-to-Growth plan works and the U.S. business re-accelerates; the bear case assumes margins and volumes remain under pressure.

What investors should know before the next session (Monday, Dec. 29)

Because the market is closed now, the most practical edge comes from being ready—mentally and mechanically—for Monday’s open.

1) Expect price discovery to restart with “thin” year-end conditions

Late December trading can amplify moves because liquidity often drops—fewer participants, wider spreads, and more gap risk. This doesn’t guarantee volatility, but it increases the odds that an ordinary headline produces a disproportionate move.

2) Re-check the dividend timeline and your position status

If your strategy involves capturing the dividend or avoiding dividend-related price adjustment dynamics, verify:

Whether you were holder-of-record as of Dec. 26, 2025
Whether your broker shows eligibility for the Jan. 9, 2026 payment ^[18]

3) Know which “turnaround proof points” the market is likely to demand next

Between now and the next earnings cycle, XRAY investors typically watch:

Signs the U.S. business is stabilizing (Q3 showed a sharp decline) ^[19]
Evidence the Return-to-Growth plan is translating into better commercial execution and not just org charts
Whether tariff/trade policy pressures ease or intensify, given management explicitly referenced them in outlook assumptions ^[20]

4) Calendar awareness: next earnings timing is approaching

Wall Street earnings calendars currently point to late February 2026 for the next report, though dates can shift and companies sometimes confirm later. ^[21]

5) Watch for weekend filings and Monday-morning “quiet” news

Even when markets are closed, companies can file updates or release statements. In a stock where leadership and strategy execution are central, any incremental disclosure—especially around finance leadership, restructuring costs, or segment performance—can matter more than broader market noise.

Bottom line

Going into the next session, XRAY sits at the intersection of a high dividend yield, a management-led turnaround plan, and a market that still wants proof.

The bullish narrative is straightforward: stabilize the U.S. business, execute the Return-to-Growth plan, and let operating performance (not impairments and uncertainty) drive the story—while shareholders collect a meaningful cash dividend along the way. ^[22]

The cautious narrative is equally straightforward: revenue pressure and execution challenges are real, guidance has been revised, and leadership transitions add friction—meaning the stock may remain “cheap for a reason” until hard numbers validate the pivot. ^[23]

References

Dentsply Sirona (XRAY) Stock Weekend Update: Dividend, Turnaround Plan, Analyst Targets—and What to Watch When Nasdaq Reopens